Nabriva Therapeutics plc provided revenue guidance for the fourth quarter of 2021. For the period, The company anticipates reporting that total revenue to grow at a mid-to-high single digit percentage as compare to third quarter of 2021's reported total revenue of $8.9 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.000001 USD | -99.00% | 0.00% | 0.00% |
2023 | Nabriva Therapeutics plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 | CI |
2023 | Nabriva Therapeutics plc(OTCPK:NBRV.F) dropped from NASDAQ Composite Index | CI |
1st Jan change | Capi. | |
---|---|---|
0.00% | 3 | |
+7.52% | 113B | |
+11.38% | 106B | |
+0.96% | 22.27B | |
-12.64% | 22.22B | |
-4.64% | 19.43B | |
-37.85% | 17.87B | |
-8.58% | 17.24B | |
+7.77% | 14.29B | |
+37.41% | 12.52B |
- Stock Market
- Equities
- NBRVF Stock
- News Nabriva Therapeutics plc
- Nabriva Therapeutics plc Provides revenue Guidance for the Fourth Quarter of 2021